Howard Lazarus, MD
Retina Specialist · New Albany, INNPI 1063411635
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,283 of the $2,991 with a category attached, or 76.3%. 20 manufacturers reported payments, led by Novartis at 40.6% of the total. Reporting peaked in 2019 at $1,408 and has fallen 77.8% since, to $312 in 2025.
Across 94 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$511
- Alimera Sciences, Inc.$258
- AbbVie$201
- Bausch & Lomb, A Division Of Bausch Health US, LLC$116
- Apellis Pharmaceuticals, Inc.$97
- plus $592 from 14 others
Across 47 payments — averaging $19,046 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$813K
- Regeneron$56K
- AstraZeneca$14K
- AbbVie$7K
- Bausch Health US, LLC$4K
- Novo Nordisk AS$841
What the payments were for
- Travel & lodging$70824%
- Food & beverage$2,28376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $1,215 |
| Regeneron Healthcare Solutions, Inc. | 23 | $511 |
| Alimera Sciences, Inc. | 14 | $258 |
| AbbVie(2 entities) | 7 | $201 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $116 |
| Apellis Pharmaceuticals, Inc. | 5 | $97 |
| Glaukos Corporation | 1 | $72 |
| Harrow Eye, LLC | 3 | $71 |
| Oyster Point Pharma, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 2 | $58 |
| Sun Pharmaceutical Industries Inc. | 2 | $53 |
| Genentech USA, Inc. | 3 | $51 |
| Alcon | 2 | $39 |
| Spark Therapeutics, Inc. | 3 | $37 |
| Aerie Pharmaceuticals, Inc. | 2 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Biogen | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,991 in reported general payments places this provider in the 65th percentile of 21 retina specialist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 55 | $25,243 |
| RestasisCyclosporine | 29 | $24,715 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $9,642 |
| Prednisolone Acetate | 158 | $4,574 |
| Difluprednate | 50 | $3,694 |
| Latanoprost | 236 | $2,315 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,211 |
| Brimonidine Tartrate | 130 | $1,590 |
| Timolol Maleate | 93 | $950 |
| Ciprofloxacin Hcl | 90 | $934 |
| Dorzolamide Hcl | 27 | $467 |
| Ketorolac Tromethamine | 22 | $440 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $430 |
| Diclofenac Sodium | 14 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $201 | $59,600125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 retina specialist providers in Indiana.
Other retina specialist in New Albany
- Ankur ShahCarmel$569K
- Raj MaturiCarmel$100K
- Ramana MoorthyCarmel$61K
- Milan ShahCarmel$35K
- Rodney BucherCarmel$30K
- Frank HrisomalosIndianapolis$4K
- Melih UstaogluTerre Haute$4K
- Julia HudsonCarmel$3K
- Steven VirataLafayette$1K
- Alexander IzadTerre Haute$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.